UNLOCKED: A Phase 2, Open-label Trial With KB195 in Subjects With a Urea Cycle Disorder

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 17, 2019

Primary Completion Date

February 2, 2021

Study Completion Date

March 2, 2021

Conditions
Urea Cycle Disorder
Interventions
DRUG

KB195

KB195 is a novel glycan

Trial Locations (19)

1200

Cliniques Universitaires Saint-Luc, Brussels

3010

Inselpital, Universitaetsklinik fur Kinderheikunde, Bern

Inselpital, Universitätsklinik für Kinderheilkunde, Bern

9000

Universitair Ziekenhuis Gent, Ghent

10029

Icahn School of Medicine at Mount Sinai-Clinical Research Unit, New York

12105

Johns Hopkins University School of Medicine, Baltimore

14004

Hospital Universitario Reina Sofia, Córdoba

15224

UPMC Children's Hospital of Pittsburgh, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

33606

University of South Florida/ USF HEALTH, Tampa

41013

Hospital Universitario Virgen del Rocio, Seville

48903

Hospital de Cruces, Barakaldo

63110

Washington University School of Medicine, St Louis

69120

Zentrum für Kinder- und Jugendmedizin Angelika-Lautenschläger-Klinik, Heidelberg

08035

Hosptial Universitari Vall d'Hebron, Barcelona

Unknown

Department of Child Health and Diseases, Department of Nutrition and Metabolism Istanbul University, Istanbul

M68HD

Salford Royal Hospital, Salford

Salford Royal NHS Foundation Trust, Salford

WC1N3BG

National Hospital for Neurology and Neurosurgery, London

Sponsors
All Listed Sponsors
lead

Kaleido Biosciences

INDUSTRY